Renasight™ Kidney Gene Panel
Use
Renasight is a genetic test designed to identify potential genetic causes for individuals with kidney disease or increased hereditary risk due to family history. The test analyzes 397 genes associated with chronic kidney disease (CKD) using next-generation sequencing. It aims to provide valuable information that can aid in disease management, predict disease progression, and influence treatment decisions. By identifying genetic predispositions, the test can also inform family members who may be at risk and guide participation in clinical trials for advanced treatments.
Special Instructions
Renasight offers convenient remote testing services, including virtual ordering for providers and at-home sample collection for patients through saliva or mobile blood draw. The service includes complimentary information sessions with board-certified genetic counselors. The test requires provider-initiated ordering, and the samples can be collected at a clinic or at home. Results are typically available for review in about three weeks.
Limitations
The Renasight test has a turnaround time of approximately three weeks. It analyzes a curated panel of 397 genes relevant to chronic kidney disease but may not cover all possible genetic mutations that could cause or contribute to kidney disease. Variants of uncertain significance (VUS) might be identified, which could require further investigation and clinical correlation. The test is not FDA-approved, and its results should be interpreted within the context of clinical presentation and family history.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided